Indication: Depression: Fluoxetine hydrochloride capsules are used to treat depressive symptoms with or without anxiety symptoms, especially when sedation is not required. Obsessive-compulsive disorder. Bulimia nervosa: Fluoxetine hydrochloride capsules are used to reduce binge eating and cathartic behaviors.

Indication: Depression: Fluoxetine hydrochloride capsules are used to treat depressive symptoms with or without anxiety symptoms, especially when sedation is not required. Obsessive-compulsive disorder. Bulimia nervosa: Fluoxetine hydrochloride capsules are used to reduce binge eating and cathartic behaviors.

Indication: Depression: Fluoxetine hydrochloride capsules are used to treat depressive symptoms with or without anxiety symptoms, especially when sedation is not required. Obsessive-compulsive disorder. Bulimia nervosa: Fluoxetine hydrochloride capsules are used to reduce binge eating and cathartic behaviors.

Indication: Depression: Fluoxetine hydrochloride capsules are used to treat depressive symptoms with or without anxiety symptoms, especially when sedation is not required. Obsessive-compulsive disorder. Bulimia nervosa: Fluoxetine hydrochloride capsules are used to reduce binge eating and cathartic behaviors.

Indication: 1. Depression: Proxel is used to treat depressive symptoms with or without anxiety symptoms. 2. Obsessive-compulsive disorder: Proxel is used to treat obsessive thoughts and compulsive behaviors with or without depression. 3. Bulimia nervosa: Proxel is used to relieve bulimia and purgative behaviors with or without depression.

Indication: Fluoxetine is indicated for the treatment of: Acute and maintenance treatment of Major Depressive Disorder [ see Clinical Studies (14. 1) Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) [ see Clinical Studies (14. 2) Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa [ see Clinical Studies (14. 3) Acute treatment of Panic Disorder, with or without agoraphobia [ see Clinical Studies (14. 4) Fluoxetine monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant depression. Fluoxetine is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) (1) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) (1) Acute and maintenance treatment of Bulimia Nervosa (1) Acute treatment of Panic Disorder, with or without agoraphobia (1).

Indication: Fluoxetine is a a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years (1. 1) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adults and pediatric patients aged 7 to 17 years (1. 2) Acute and maintenance treatment of Bulimia Nervosa in adult patients (1. 3) Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients (1. 4) Fluoxetine tablets are indicated for the acute and maintenance treatment of Major Depressive Disorder in adult patients and in pediatric patients aged 8 to18 years [see Clinical Studies (14. 1) The usefulness of the drug in adult and pediatric patients receiving fluoxetine for extended periods should periodically be re-evaluated [see Dosage and Administration (2. 1) Fluoxetine tablets are indicated for the acute and maintenance treatment of obsessions and compulsions in adult patients and in pediatric patients aged 7 to 17 years with Obsessive Compulsive Disorder (OCD) [see Clinical Studies (14. 2) The effectiveness of fluoxetine tablets in long-term use, i. , for more than 13 weeks, has not been systematically evaluated in placebo-controlled trials. Therefore, the physician who elects to use fluoxetine tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see Dosage and Administration (2. 2) Fluoxetine tablets are indicated for the acute and maintenance treatment of binge-eating and vomiting behaviors in adult patients with moderate to severe Bulimia Nervosa [see Clinical Studies (14. 3) The physician who elects to use fluoxetine tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see Dosage and Administration (2. 3 ) Fluoxetine tablets are indicated for the acute treatment of Panic Disorder, with or without agoraphobia, in adult patients [see Clinical Studies (14. 4) The effectiveness of fluoxetine tablets in long-term use, i. , for more than 12 weeks, has not been established in placebo-controlled trials.

Indication: Fluoxetine tablets are indicated for the treatment of: Major Depressive Disorder (MDD). The efficacy of fluoxetine in MDD was established in one 5-week trial, three 6-week trials, and one maintenance study in adults. The efficacy of fluoxetine was also established in two 8- to 9-week trials in pediatric patients 8 to 18 years of age [see Clinical Studies ( 14. 1 Obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD). The efficacy of fluoxetine in OCD was demonstrated in two 13-week trials in adults and one 13-week trial in pediatric patients 7 to 17 years of age [see Clinical Studies ( 14. 2 Binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa. The efficacy of fluoxetine in Bulimia Nervosa was demonstrated in two 8-week trials and one 16-week trial in adults [see Clinical Studies ( 14. 3 Panic Disorder, with or without agoraphobia. The efficacy of fluoxetine in Panic Disorder was demonstrated in two 12-week trials in adults [see Clinical Studies ( 14. 4 Fluoxetine tablets are a selective serotonin reuptake inhibitor indicated (SSRI) the treatment of: Major Depressive Disorder (MDD) ( 1 Adults: Efficacy was established in one 5-week trial, three 6-week trials, and one maintenance study ( 14. 1 Pediatrics: Efficacy was established in two 8-to 9-week trials of patients aged 8 to 18 years ( 14. 1 Obsessive Compulsive Disorder (OCD) ( 1 Adults: Efficacy was established in two 13-week trials ( 14. 2 Pediatrics: Efficacy was established in one 13-week trial in patients aged 7 to 17 years ( 14. 2 Bulimia Nervosa ( 1 Adults: Efficacy was established in two 8-week trials and one 16-week trial ( 14. 3 Panic Disorder, with or without agoraphobia ( 1 Adults: Efficacy was established in two 12-week trials ( 14.

Indication: Fluoxetine is indicated for the treatment of: Acute and maintenance treatment of Major Depressive Disorder [see Clinical Studies (14. 1) Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) [see Clinical Studies (14. 2) Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa [see Clinical Studies (14. 3) Acute treatment of Panic Disorder, with or without agoraphobia [see Clinical Studies (14. 4) Fluoxetine and Olanzapine in Combination is indicated for the treatment of: Acute treatment of depressive episodes associated with Bipolar I Disorder. Fluoxetine monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder. registered Fluoxetine capsules are a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) ( 1 Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) ( 1 Acute and maintenance treatment of Bulimia Nervosa ( 1 Acute treatment of Panic Disorder, with or without agoraphobia ( 1 Fluoxetine capsules and olanzapine in combination for treatment of: Acute Depressive Episodes Associated with Bipolar I Disorder ( 1.

Indication: Fluoxetine capsules are indicated for the treatment of: Acute and maintenance treatment of Major Depressive Disorder [see Clinical Studies (14. 1) Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) [see Clinical Studies (14. 2) Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa [see Clinical Studies (14. 3) Acute treatment of Panic Disorder, with or without agoraphobia [see Clinical Studies (14. 4) Fluoxetine capsules and Olanzapine in Combination are indicated for the treatment of: Acute treatment of depressive episodes associated with Bipolar I Disorder. Treatment resistant depression (Major Depressive Disorder in patients, who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). Fluoxetine capsules monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant depression. registered Fluoxetine capsules are a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) ( 1 Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) ( 1 Acute and maintenance treatment of Bulimia Nervosa ( 1 Acute treatment of Panic Disorder, with or without agoraphobia ( 1 Fluoxetine capsules and olanzapine in combination for treatment of: Acute Depressive Episodes Associated with Bipolar I Disorder ( 1 Treatment Resistant Depression ( 1.